AuctuCel launches AuctuPrime cell culture medium
Analysis based on 6 articles · First reported Aug 04, 2026 · Last updated Aug 10, 2026
The launch of AuctuPrime could enhance AuctuCel's competitive position in the cell therapy manufacturing market, potentially attracting partnerships and customers seeking more reproducible and xeno-free culture media. This may positively influence investor sentiment toward AuctuCel and its collaborator Sperikon, while also supporting the broader advanced therapy sector in Singapore and Malaysia.
On 4 August 2026, Singapore-based biotechnology company AuctuCel announced the launch of AuctuPrime, a next-generation chemically defined cell culture medium developed in collaboration with Sperikon. The product is designed to eliminate dependence on animal serum and donor-derived human platelet supplements in cell therapy manufacturing, aiming to reduce batch-to-batch variability and improve supply chain resilience. The launch aligns with Singapore's and Malaysia's efforts to strengthen their advanced therapy ecosystems, with the Singapore — Economic Development Board reporting a fourfold increase in locally incorporated biotech companies since 2015 and Malaysia's Malaysia — National Pharmaceutical Regulatory Agency updating cell and gene therapy guidance in September 2025. AuctuCel, spun out of Singapore — Agency for Science, Technology and Research's Bioprocessing Technology Institute, positions AuctuPrime as a manufacturing input to support reproducible scale-up from research to clinical and commercial production. Company executives Dr Zach Pang and Dr Chee Wai Fhu emphasized the importance of consistent manufacturing for advancing regenerative medicine.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard